More case studies
How CSI rescued an oncology trial when a competitor failed to deliver, despite an extremely tight deadline and scarce supply on the market
Rescuing a Global Biotech's Oncology Study with Cetuximab
How CSI used its scientific expertise at the protocol stage to provide flexibility in sourcing strategy and ensure high volumes of a single product were supplied on time to multiple countries
Delivering Comparators for a Global Allergy Study
How CSI’s regulatory guidance and robust sourcing solutions ensured the success of a global flu vaccine trial that could not afford to run behind schedule
Sourcing Flu Vaccines for a Global Trial
CSI was approached by a Clinical Research Organisation (CRO) conducting a full global Phase 3 oncology study spanning 14 countries. We were asked to purchase and supply a significant quantity of ruxolitinib within a tight timeframe: with the contract signed in December 2022, the client aimed to have the first sites supplied by March 2023. The client also required three annual resupplies of the oncology medicine to be factored into the request.
Within eight weeks, the entire study setup had been meticulously organised, ensuring the smooth and timely execution of the clinical trial supply chain. CSI’s strong relationships with manufacturers around the world and outstanding access to oncology products allowed for the procurement of a substantial volume of ruxolitinib within a short timeframe. CSI’s global depot network facilitated the efficient delivery of the oncology medication without delay – just in time for the client’s tight deadline.
CSI’s scientific expertise ensured a seamless and smart study setup, with all aspects of the trial addressed meticulously in the supply planning phase. Despite the challenge of working to a tight deadline and the logistical complexities involved in coordinating product supply across 14 countries, nine depots and 67 individual site shipments, CSI successfully delivered a large quantity of the required oncology medicine in line with the client’s needs and expectations. This, in turn, allowed for Site Initiation Visits (SIVs), which had already been scheduled, to take place as planned, keeping the client’s study on track.
Global CRO Oncology Partnership
How CSI supplied large quantities of ruxolitinib to a CRO’s ongoing Phase 3 oncology study involving 14 countries, nine depots and 67 site shipments
To supply a global Phase 3 oncology study spanning 14 countries within a tight eight-week timeframe and to ensure regular resupply for three years
CSI’s manufacturer relationships and global depot network ensured a large quantity of ruxolitinib could be procured and delivered precisely when needed
Efficient supply of the required oncology product allowed for scheduled Site Initiation Visits (SIVs) to take place, keeping the client’s study on track
Get in touch with a member of our experienced team today to discuss your clinical trial supply requirements